Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

AIMS: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist tha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Heerspink, Hiddo J. L., Andress, Dennis L., Bakris, George, Brennan, John J., Correa‐Rotter, Ricardo, Dey, Jyotirmoy, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Parving, Hans‐Henrik, de Zeeuw, Dick
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2018
Soggetti:
Clinical Trial Design
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969254/
https://ncbi.nlm.nih.gov/pubmed/29405626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13245
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi